PMID- 32811535
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Aug 18
TI  - SIRT1-modified human umbilical cord mesenchymal stem cells ameliorate 
      experimental peritoneal fibrosis by inhibiting the TGF-beta/Smad3 pathway.
PG  - 362
LID - 10.1186/s13287-020-01878-2 [doi]
LID - 362
AB  - INTRODUCTION: Peritoneal fibrosis is a serious complication of long-term 
      peritoneal dialysis (PD). Combination therapies are emerging as a promising 
      treatment for tissue damage. Here, we investigated the therapeutic potential of 
      SIRT1-modified human umbilical cord mesenchymal stem cells (hUCMSCs) for 
      peritoneal fibrosis. METHODS: SIRT1 was overexpressed in hUCMSCs to establish 
      SIRT1-modified hUCMSCs. Co-culture and transplantation experiments were performed 
      in TGF-beta-stimulated Met-5A cells and peritoneal damage rodent model to assess the 
      therapeutic potential of SIRT1-modified hUCMSCs for peritoneal fibrosis through 
      qPCR, Western blot, and peritoneal function analyses. RESULTS: SIRT1-modified 
      hUCMSC administration had more potent anti-fibrosis ability than hUCMSCs, which 
      significantly inhibited the expression of fibrotic genes and suppressed EMT 
      process, increased ultrafiltration volume, and restored homeostasis of 
      bioincompatible factors in dialysis solution. Mechanistically, SIRT1-modified 
      hUCMSCs attenuated peritoneal fibrosis through reducing peritoneal inflammation 
      and inhibiting the TGF-beta/Smad3 pathway in peritoneal omentum tissues. CONCLUSION: 
      SIRT1-modified hUCMSCs might work as a promising therapeutic strategy for the 
      treatment of peritoneal dialysis-induced peritoneal damage and fibrosis.
FAU - Guo, Yanhong
AU  - Guo Y
AD  - Department of Nephropathy, The First Affiliated Hospital of Zhengzhou University, 
      No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
FAU - Wang, Liuwei
AU  - Wang L
AD  - Department of Nephropathy, The First Affiliated Hospital of Zhengzhou University, 
      No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
FAU - Gou, Rong
AU  - Gou R
AD  - Department of Nephropathy, The First Affiliated Hospital of Zhengzhou University, 
      No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
FAU - Wang, Yulin
AU  - Wang Y
AD  - Department of Nephropathy, The First Affiliated Hospital of Zhengzhou University, 
      No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
FAU - Shi, Xiujie
AU  - Shi X
AD  - Department of Nephropathy, Henan Provincial Hospital of Traditional Chinese 
      Medicine (The Second Hospital Affiliated to Henan University of Chinese 
      Medicine), No. 6, Dong Feng Road, Jinshui District, Zhengzhou, 450002, Henan, 
      China.
FAU - Pang, Xinxin
AU  - Pang X
AD  - Department of Nephropathy, Henan Provincial Hospital of Traditional Chinese 
      Medicine (The Second Hospital Affiliated to Henan University of Chinese 
      Medicine), No. 6, Dong Feng Road, Jinshui District, Zhengzhou, 450002, Henan, 
      China. doctorpang@aliyun.com.
FAU - Tang, Lin
AU  - Tang L
AD  - Department of Nephropathy, The First Affiliated Hospital of Zhengzhou University, 
      No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China. tanglin@zzu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200818
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
RN  - 0 (SMAD3 protein, human)
RN  - 0 (Smad3 Protein)
RN  - 0 (Transforming Growth Factor beta)
RN  - EC 3.5.1.- (SIRT1 protein, human)
RN  - EC 3.5.1.- (Sirtuin 1)
SB  - IM
MH  - Humans
MH  - *Mesenchymal Stem Cells/metabolism
MH  - *Peritoneal Fibrosis/genetics/therapy
MH  - Sirtuin 1/genetics
MH  - Smad3 Protein/genetics
MH  - Transforming Growth Factor beta/genetics/metabolism
MH  - Umbilical Cord/metabolism
PMC - PMC7436980
OTO - NOTNLM
OT  - EMT
OT  - Peritoneal fibrosis
OT  - SIRT1
OT  - TGF-beta
OT  - hUCMSCs
COIS- The authors declare that there is no conflict of interests.
EDAT- 2020/08/20 06:00
MHDA- 2021/06/22 06:00
PMCR- 2020/08/18
CRDT- 2020/08/20 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/07/01 00:00 [revised]
PHST- 2020/08/20 06:00 [entrez]
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/08/18 00:00 [pmc-release]
AID - 10.1186/s13287-020-01878-2 [pii]
AID - 1878 [pii]
AID - 10.1186/s13287-020-01878-2 [doi]
PST - epublish
SO  - Stem Cell Res Ther. 2020 Aug 18;11(1):362. doi: 10.1186/s13287-020-01878-2.